Innate Pharma: PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027

What happened: Innate Pharma said AstraZeneca updated the expected timing for the PACIFIC-9 Phase 3 trial high-level data readout to the first half of 2027, from the second half of 2026 previously. Key numbers: Readout moved to H1 2027 from H2 2026. Enrollment in the trial is complete. AstraZeneca obtained full oncology rights to monalizumab in October 2018. Why it matters: Innate said the revised timing reflects the event-driven nature of the study. PACIFIC-9 evaluates durvalumab with monalizumab or oleclumab in unresectable Stage III NSCLC. Market: +0.3% today ($172.06), -5.1% YTD, 1.2x vol — as of 22:46 UTC

Innate Pharma said AstraZeneca updated the expected timing for the PACIFIC-9 Phase 3 trial high-level data readout to the first half of 2027, from the second half of 2026 previously.

Innate said the revised timing reflects the event-driven nature of the study. PACIFIC-9 evaluates durvalumab with monalizumab or oleclumab in unresectable Stage III NSCLC. Market: +0.3% today ($172.06), -5.1% YTD, 1.2x vol — as of 22:46 UTC